Prodia Subsidiary (PRDL) Sets IPO Price at Rp 120 per Share

PT Prodia Diagnostic Line commenced its initial public offering (IPO) period today, Wednesday (1/7/2026). The prospective issuer, which will trade under the ticker code PRDL, has set the offering price at Rp 120 per share. This price represents the upper limit of the indicative range of Rp 100 to Rp 120 per share stated in the IPO prospectus. PRDL is offering a maximum of 522.9 million new shares, equivalent to 30% of its issued and fully paid capital post-IPO. Consequently, the Prodia Group subsidiary aims to raise fresh funds of Rp 62.75 billion. Of the total proceeds, approximately Rp 35.67 billion will be used to repay the principal of loans to PT Bank Central Asia Tbk. (BCA) and PT Bank Pan Indonesia Tbk. (Panin Bank). In terms of financial performance, PRDL’s net profit reached approximately Rp 35.8 billion in 2023, before dropping sharply to Rp 10 billion in 2024 and subsequently recovering to around Rp 17 billion in 2025. PRDL is a company engaged in the manufacture and processing of medical devices for medical diagnosis, or in vitro diagnostics (IVD). The company has a production facility in the Jababeka III Industrial Estate, Cikarang, West Java. The listing of PRDL shares on the Indonesia Stock Exchange (BEI) is scheduled for 9 July 2026.